AREXVY GlaxoSmithKline Australia Pty Ltd
Product name
AREXVY
Accepted date
Apr-2024
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Proposed indication
For the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Application type
C (new medicine)
Publication date
Apr-2024